Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASBP NASDAQ:IOBT NASDAQ:REVB NASDAQ:VIVS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASBPAspire Biopharma$5.87+10.8%$21.35$3.31▼$1,050.36$890K0.211.36 million shs199,273 shsIOBTIO Biotech$0.05$0.11$0.03▼$2.79$3.45M0.887.09 million shsN/AREVBRevelation Biosciences$1.03-1.9%$1.17$0.88▼$39.60$4.10M-0.1488,856 shs26,945 shsVIVSVivoSim Labs$1.32+1.5%$1.59$1.25▼$5.30$3.39M1.4151,621 shs15,517 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASBPAspire Biopharma+10.75%+26.24%-83.56%-86.32%+586,999,900.00%IOBTIO Biotech0.00%0.00%0.00%-87.01%-95.10%REVBRevelation Biosciences-1.90%+0.98%-14.17%-29.93%-97.26%VIVSVivoSim Labs+1.54%-6.38%-13.16%-34.00%+131,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASBPAspire Biopharma$5.87+10.8%$21.35$3.31▼$1,050.36$890K0.211.36 million shs199,273 shsIOBTIO Biotech$0.05$0.11$0.03▼$2.79$3.45M0.887.09 million shsN/AREVBRevelation Biosciences$1.03-1.9%$1.17$0.88▼$39.60$4.10M-0.1488,856 shs26,945 shsVIVSVivoSim Labs$1.32+1.5%$1.59$1.25▼$5.30$3.39M1.4151,621 shs15,517 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASBPAspire Biopharma+10.75%+26.24%-83.56%-86.32%+586,999,900.00%IOBTIO Biotech0.00%0.00%0.00%-87.01%-95.10%REVBRevelation Biosciences-1.90%+0.98%-14.17%-29.93%-97.26%VIVSVivoSim Labs+1.54%-6.38%-13.16%-34.00%+131,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASBPAspire Biopharma 1.00SellN/AN/AIOBTIO Biotech 1.60Reduce$3.507,191.67% UpsideREVBRevelation Biosciences 1.00SellN/AN/AVIVSVivoSim Labs 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest ASBP, VIVS, REVB, and IOBT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2026REVBRevelation Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)5/7/2026VIVSVivoSim Labs Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/27/2026REVBRevelation Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)4/20/2026ASBPAspire Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026IOBTIO Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASBPAspire Biopharma$10K99.79N/AN/A($54.19) per share-0.11IOBTIO BiotechN/AN/AN/AN/A$0.71 per shareN/AREVBRevelation BiosciencesN/AN/AN/AN/A$3.32 per shareN/AVIVSVivoSim Labs$140K24.61N/AN/A$5.54 per share0.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASBPAspire Biopharma-$24.48M-$20.00N/AN/AN/AN/AN/A-1,468.13%N/AIOBTIO Biotech-$95.49M-$1.35N/AN/AN/AN/A-517.22%-200.69%N/AREVBRevelation Biosciences-$8.91M-$39.48N/AN/AN/AN/A-107.65%-87.98%N/AVIVSVivoSim Labs-$2.48M-$3.15N/AN/AN/A-861.27%-15.51%-11.31%N/ALatest ASBP, VIVS, REVB, and IOBT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026REVBRevelation Biosciences-$1.15-$2.71-$1.56-$2.71N/AN/A3/30/2026Q4 2025ASBPAspire BiopharmaN/A-$1.65N/A-$15.95N/A$0.00 million2/26/2026Q4 2025REVBRevelation Biosciences-$1.41-$1.65-$0.24-$1.65N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthASBPAspire BiopharmaN/AN/AN/AN/AN/AIOBTIO BiotechN/AN/AN/AN/AN/AREVBRevelation BiosciencesN/AN/AN/AN/AN/AVIVSVivoSim LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASBPAspire BiopharmaN/A0.170.14IOBTIO Biotech18.292.012.01REVBRevelation BiosciencesN/A10.025.41VIVSVivoSim LabsN/A2.442.44Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASBPAspire Biopharma19.17%IOBTIO Biotech54.76%REVBRevelation Biosciences12.80%VIVSVivoSim Labs8.23%Insider OwnershipCompanyInsider OwnershipASBPAspire Biopharma5.80%IOBTIO Biotech2.30%REVBRevelation Biosciences8.04%VIVSVivoSim Labs2.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASBPAspire BiopharmaN/A170,000157,000N/AIOBTIO Biotech3071.95 million68.50 millionNot OptionableREVBRevelation Biosciences103.91 million3.59 millionNot OptionableVIVSVivoSim Labs202.61 million2.54 millionN/AASBP, VIVS, REVB, and IOBT HeadlinesRecent News About These CompaniesVivoSim Labs IncMay 14 at 5:07 PM | cnn.comVivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human ...April 30, 2026 | bakersfield.comBVivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal TestingApril 28, 2026 | financialpost.comFVivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal TestingApril 28, 2026 | globenewswire.comVivoSim Labs, Inc. Common Stock (VIVS) Real TimeApril 7, 2026 | nasdaq.comVivoSim Announces Pricing of up to a $4 Million Public OfferingApril 1, 2026 | financialpost.comFVivoSim Announces Pricing of up to a $4 Million Public OfferingApril 1, 2026 | globenewswire.comVivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCsMarch 24, 2026 | financialpost.comFVivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCsMarch 24, 2026 | globenewswire.comVivoSim Labs Stock Price HistoryMarch 4, 2026 | investing.comVivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global SalesMarch 4, 2026 | finanznachrichten.deVivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global SalesMarch 3, 2026 | financialpost.comFVivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global SalesMarch 3, 2026 | globenewswire.comVivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San DiegoFebruary 11, 2026 | financialpost.comFVivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San DiegoFebruary 11, 2026 | globenewswire.comVivoSim Labs, Inc. Common Stock (VIVS) Analyst ResearchFebruary 4, 2026 | nasdaq.comWhy is VIVS stock up 79% today?January 30, 2026 | msn.comVivoSim Labs Expands Commercial Presence in Asia-Pacific with Distribution Agreements in Korea and China for NAMKind™ Toxicology ServicesJanuary 29, 2026 | quiverquant.comQVivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and ChinaJanuary 29, 2026 | financialpost.comFVivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and ChinaJanuary 29, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeASBP, VIVS, REVB, and IOBT Company DescriptionsAspire Biopharma NASDAQ:ASBP$5.87 +0.57 (+10.75%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$5.64 -0.23 (-3.90%) As of 08:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.IO Biotech NASDAQ:IOBT$0.05 0.00 (0.00%) As of 04/7/2026IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.Revelation Biosciences NASDAQ:REVB$1.03 -0.02 (-1.90%) Closing price 05/14/2026 03:58 PM EasternExtended Trading$0.96 -0.07 (-6.70%) As of 07:37 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.VivoSim Labs NASDAQ:VIVS$1.32 +0.02 (+1.54%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$1.38 +0.05 (+4.17%) As of 08:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies 2 Ways to Play the Big Pharma Patent Cliff Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
